Via San Marco, 23 • 33099 • Vivaro PN • Italy
Friulchem S.p.A., a
Vivaro, Italy-based contract development and manufacturing organization for
innovator and generic pharmaceutical products for human and veterinary use,
reports on manufacturing developments for rifaximin, an active pharmaceutical
ingredient (API) used to treat travelers' diarrhea in adults and children
12-years of age and older. Rifaximin has also been evaluated for treating
hepatic encephalopathy, infectious diarrhea, diverticular disease, and as an
antibacterial prophylactic before colon surgery.
Rifaximin is a semi-synthetic product derived from fermentation and that shows many polymorphs, most of them are covered by patent (alpha-, beta-, gamma-, and delta-forms). The alpha-polymorph is the most active. It cannot be absorbed, so its intestinal action is local, according to information from Friulchem.
Friulchem has patented another polymorph, a pseudo-crystalline solid form, FC rifaximin, derived from rifamycin O. The FC patent was filled in 2011 in Europe, Mexico, and the US (PCT/EP2011/058171), and the patent has been granted in Europe and the US.
FC rifaximin is stable at different contents of water (% KF 2.00 - 4.45) and is distinct from the other patented forms (alpha, beta, and gamma), according to the company. It will be available in 200-mg and 550-mg film-coated tablets for human use.
FC-rifaximin can also be used in veterinary applications. Friulchem has identified a different manufacturing method for a chewable matrix without the limitation related to production by extrusion.
Due to the high palatability showed in preliminary tests, FC-cubes may be used to prepare formulations that can include different APIs, including rifaximin. The matrix composition is 100% palatable and able to mask also active components that are disliked by animals, according to the company.
Contact firstname.lastname@example.org for more information.Read More
The log-in process has been changed. If you have trouble logging into your company profile please click here.